within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01D_CytotoxicAntibioticsAndRelatedSubstances.L01DC04_Ixabepilone;

model Ixabepilone
  extends Pharmacolibrary.Drugs.ATC.L.L01DC04;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01DC04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ixabepilone is a semisynthetic analog of epothilone B, classified as an antineoplastic agent. It is a microtubule inhibitor used primarily in the treatment of metastatic or locally advanced breast cancer, particularly in cases that are resistant to anthracyclines and taxanes. Ixabepilone is approved for intravenous use in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in cancer patients following a single intravenous infusion of 40 mg/m2 over 3 hours.</p><h4>References</h4><ol><li><p>Aghajanian, C, et al., &amp; O&#x27;Connor, OA (2007). Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 25(9) 1082–1088. DOI:<a href=&quot;https://doi.org/10.1200/JCO.2006.08.7304&quot;>10.1200/JCO.2006.08.7304</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17261851/&quot;>https://pubmed.ncbi.nlm.nih.gov/17261851</a></p></li><li><p>Deeken, JF, et al., &amp; LoRusso, PM (2014). A phase I study of oral ixabepilone in patients with advanced solid tumors. <i>Cancer chemotherapy and pharmacology</i> 73(5) 1071–1078. DOI:<a href=&quot;https://doi.org/10.1007/s00280-014-2443-7&quot;>10.1007/s00280-014-2443-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24663504/&quot;>https://pubmed.ncbi.nlm.nih.gov/24663504</a></p></li><li><p>Beumer, JH, et al., &amp; Schellens, JH (2007). Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. <i>Investigational new drugs</i> 25(4) 327–334. DOI:<a href=&quot;https://doi.org/10.1007/s10637-007-9041-z&quot;>10.1007/s10637-007-9041-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17347871/&quot;>https://pubmed.ncbi.nlm.nih.gov/17347871</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Ixabepilone;
